Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Sep 27, 2022 3:24pm
147 Views
Post# 34990231

And Tesamorelin reduces visceral fat…

And Tesamorelin reduces visceral fat…

“Nonalcoholic fatty liver disease, or NAFLD, affects approximately 25% of the general adult population in the United States. But unfortunately, patients or people living with HIV are at a higher risk. Previous studies have shown that approximately 35% of HIV patients have evidence of NAFLD and that they tend to progress more rapidly in terms of fibrosis stages, which can lead to complications including the development of cirrhosis and possibly liver cancer. So, people with HIV are at a higher risk of developing fatty liver disease and progressing to more advanced forms of fatty liver.

 

When we think of different types of fat, we think of visceral fat or visceral adipose tissue compared to subcutaneous adipose tissue, and visceral adipose tissue is more metabolically active and can actually cause more fat deposition and release by the release of fatty acids through the portal circulation, and these free fatty acids can be deposited in the liver cells and lead to the formation of triglycerides and lipid droplets. And this is really the beginning of non-alcoholic fatty liver disease, which can lead to further liver inflammation, liver cell damage and eventually the development of liver fibrosis…”

 

https://letterspedia.com/the-relationship-between-waist-circumference-liver-disease/

<< Previous
Bullboard Posts
Next >>